Hola,
Are you new here?

I have an account

Conecta con

+150K Projects

+300K Companies

+230 Financiaciones

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

BRIGHT

financed

Closed

Treat severe cases of infection at COV with XAV 19

Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimized safety. It has been known for decades that polyclonal antibodies are very efficient wea... see more

31/12/2022

Xenothera

3M€

Project Budget: 3M€

Project leader

XENOTHERA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2022-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada does 5 years

0% 69% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Xenothera

2.16M€ | Leader

KRAFFT

1.20M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 29 months Date Start: 2020-07-27
End date: 2022-12-31

Project leader

XENOTHERA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 3M€

participation deadline Sin fecha límite de participación.

Project description Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimized safety. It has been known for decades that polyclonal antibodies are very efficient weapons in infectious diseases, either bacterial or viral, and they are established as superior to monoclonal in various viral infections. Since the beginning of the pandemic XENOTHERA has initiated a project to develop a new treatment against COVID-19 based on its technology. The product is named XAV-19 and is expected to treat patients suffering from moderate to severe pneumonia. The purpose of BRIGHT is to prepare the product, run all necessary investigation so that we can safely run a clinical trial demonstrating the efficacy of the product. This will be a phase 2 double-blind clinical trial of XAV19 versus placebo. The endpoint will be the quick recovery of patients admitted at the hospital.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers

What is innovating.Works? Lose yourself in the best search engine for innovative companies you've ever seen, see how your competition is funded, connect with that partner you didn't know about, discover R&D projects that need you, and much, much more just a click away.

Smart Company-Financial Motor Innovating tiene un perfil tecnológico financiero de 400.000 empresas gracias al cual sabe a qué ayuda puede ir o no cualquier empresa de forma automática. Parece magia pero es tecnología.

Create your project and find partners ¿Tienes un proyecto y buscas un partner? Una Universidad, Centro Tecnológico, Consultoría? Este es tu sitio. Gracias al motor de búsqueda podemos recomendarte los mejores socios y ponerte en contacto con ellos.